Johnson & Johnson (JNJ) 108.20 $JNJ
Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain
PR Newswire - Thu Mar 31, 3:10PM CDT
Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that it is discontinuing the Phase 3 development program for fulranumab in osteoarthritis pain. This decision was based on strategic portfolio prioritization and was not based on any emerging safety concerns from the Phase 3 clinical studies with fulranumab. Janssen Pharmaceuticals, Inc., an affiliated company, is terminating its licensing agreement with Amgen Inc. for fulranumab and is returning all program rights back to Amgen.
JNJ: 108.20 (-0.78), AMGN: 149.93 (+0.45)
Johnson & Johnson Correction Could Equal Buying Opportunity
at The Street - Thu Mar 31, 2:16PM CDT
Shares of the pharmaceutical company are headed in the right direction, but the pace of the rally is slowing.
JNJ: 108.20 (-0.78)
Potential Johnson & Johnson Correction Could Equal Buying Opportunity
at The Street - Thu Mar 31, 2:16PM CDT
Shares of the pharmaceutical company are headed in the right direction, but the pace of the rally is slowing.
JNJ: 108.20 (-0.78)
Pfizer Tops List of Best Biopharmaceutical Brands
at The Street - Thu Mar 31, 1:09PM CDT
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.
JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), AZN: 28.16 (-0.16), MRK: 52.91 (-0.31), PFE: 29.64 (-0.43), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11)
Jim Cramer: Johnson & Johson, IBM, Alphabet Are Cheaper Than You Think
at The Street - Thu Mar 31, 11:35AM CDT
Jim Cramer discusses why stocks like Johnson & Johnson, IBM and Alphabet are cheap as we head into the second quarter.
JNJ: 108.20 (-0.78), GE: 31.79 (-0.04), CLX: 126.06 (-1.91), IBM: 151.45 (+3.04), DAL: 48.68 (-0.65), UNH: 128.90 (-0.78), KMB: 134.51 (-1.20), MCD: 125.68 (-0.15), AAL: 41.01 (-0.37), GOOGL: 762.90 (-5.44), VZ: 54.08 (+0.04), UAL: 59.86 (+0.04)
Medivation Surges on Takeover Chatter; Wall Street Scouts for Big Pharma M&A
at The Street - Thu Mar 31, 7:10AM CDT
Medivation is surging as Wall Street scouts the Big Pharma front for discounted M&A opportunities.
MDVN: 45.98 (+8.59), JNJ: 108.20 (-0.78), VRX: 26.30 (-0.77)
Jim Cramer's 'Mad Money' Recap: Here's How Janet Yellen Set You Free
at The Street - Wed Mar 30, 7:13PM CDT
We no longer have to fear the Fed because the central bank has acknowledged our economy is fragile and the strong U.S. dollar is only making things worse, says Cramer.
KMI: 17.86 (unch), MMM: 166.63 (-0.12), GE: 31.79 (-0.04), ETN: 62.56 (-0.19), EW: 88.21 (-0.68), LLY: 72.01 (+0.23), XRX: 11.16 (+0.33), SCI: 24.68 (+0.33), MTZ: 20.24 (+0.07), PVH: 99.06 (+0.14), NFLX: 102.23 (+0.04), JNJ: 108.20 (-0.78), PAYX: 54.01 (+0.72), TJX: 78.35 (-0.33), DPZ: 131.86 (+0.89), HBI: 28.34 (-0.14), ROST: 57.90 (-0.44)
Cramer Says Stryker an Attractive Target for Johnson & Johnson
at The Street - Wed Mar 30, 2:58PM CDT
As Johnson & Johnson surveys the M&A scene, investors would be wise to keep Stryker on their radars, Real Money's Jim Cramer says.
JNJ: 108.20 (-0.78), SYK: 107.29 (+0.24)
Kellton Tech Enriches SAP Expertise Through Acquisitions
PRWeb - Wed Mar 30, 8:55AM CDT
Kellton Tech, a global, publicly listed IT company based in Hyderabad, India, successively acquired two US-based enterprise solutions providers in the last year to strengthen its capabilities in SAP.
JNJ: 108.20 (-0.78), NWL: 44.29 (-0.08)
4 Value Stocks to Buy Now
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:43AM CDT
U.S. stock markets have been choppy this year, thanks to gyrations in oil price movements. This volatility makes investing in value stocks more appealing.
HCA: 78.05 (-0.05), JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), TGT: 82.28 (-1.32)
X-Chem Announces License with Janssen for Protein
rotein Inhibitor Program in Inflammatory Disease
BusinessWire - Wed Mar 30, 7:15AM CDT
X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX(TM)) drug discovery platform to generate novel therapeutics, today announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been exercised for a protein inhibitor program of inflammatory disease. The licensed program comprises cell-active, potent small molecules that inhibit a difficult-to-drug protein ligand-receptor interaction. Janssen exercised its license option under an agreement to discover new treatments for inflammatory disease established by the companies in December 2014. The licensing event triggers a milestone payment under the collaboration agreement; X-Chem is eligible to receive future payments linked to the achievement of defined milestones, as well as royalties.
JNJ: 108.20 (-0.78)
Global Antibiotics Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Bayer Healthcare, GlaxoSmithKline, Johnson & Johnson - Research and Markets
BusinessWire - Tue Mar 29, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3g2qr4/antibiotics) has announced the addition of the "Antibiotics: Technologies and Global Markets" report to their offering.
JNJ: 108.20 (-0.78), GSK: 40.55 (-0.15)
How 16 Ex-Military CEOs are Trouncing Wall Street
at The Street - Mon Mar 28, 3:44PM CDT
Putting your money into these 16 companies, whose CEOs served in the U.S. military, would have left you (a lot) richer than just following the S&P 500.
FDX: 162.72 (+1.15), NSC: 83.25 (-1.50), CAM: 67.05 (-0.63), AAP: 160.34 (-3.45), PCG: 59.72 (+0.28), SNA: 156.99 (-1.55), RTN: 122.63 (-1.13), AMT: 102.37 (+0.06), SLB: 73.75 (-0.66), CELG: 100.09 (+1.29), SJM: 129.84 (-0.34), JNJ: 108.20 (-0.78), VNO: 94.43 (+0.46), CSC: 34.39 (+0.36), EQIX: 330.71 (+2.60), CSRA: 26.90 (-0.29), VZ: 54.08 (+0.04)
Johnson & Johnson to Webcast Annual Meeting of Shareholders
PR Newswire - Mon Mar 28, 3:44PM CDT
Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10:00 a.m. (EDT) on Thursday, April 28, 2016, from the State Theatre in New Brunswick, N.J.
JNJ: 108.20 (-0.78)
Shock and Awe: West Point Grads Use Military Strategy to Win Big as CEOs
at The Street - Mon Mar 28, 3:23PM CDT
How can West Point help your stock returns? West Point graduates leading Johnson & Johnson, Equinix, and Cameron International posted an average yearly return of 34% while the S&P declined.
JNJ: 108.20 (-0.78), CAM: 67.05 (-0.63), EQIX: 330.71 (+2.60)
Rising Through the Ranks: Interview with Johnson & Johnson CEO Alex Gorsky
at The Street - Mon Mar 28, 3:20PM CDT
Influenced by his father's service in the Korean War, Alex Gorsky said that since he was a boy he dreamed of attending the U.S. Military Academy at West Point.
JNJ: 108.20 (-0.78)
ADM Board of Directors Nominates Debra A. Sandler to Board
BusinessWire - Mon Mar 28, 10:00AM CDT
Archer Daniels Midland Company (NYSE: ADM) today announced that its Board of Directors has nominated Debra A. Sandler to stand for election to the board at its upcoming Annual Stockholders' Meeting on May 5, 2016. Sandler's prior experience includes senior leadership positions at Mars, Inc., Johnson & Johnson, and PepsiCo. Most recently she served as Chief Health and Wellbeing Officer at Mars, after serving there as Chief Consumer Officer and President of Mars Chocolate North America. Sandler currently sits on the board of Gannett Co., Inc.
JNJ: 108.20 (-0.78), ADM: 36.31 (-0.31), GCI: 15.14 (-0.26)
4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 108.20 (-0.78), VRX: 26.30 (-0.77), SYN: 2.36 (+0.03), GERN: 2.92 (+0.05), AMGN: 149.93 (+0.45), EPZM: 12.12 (+0.61), CORT: 4.68 (+0.41)
Legal-Bay Says J&J Moves to Settle Morcellator Suits
PR Newswire - Mon Mar 28, 4:00AM CDT
Legal-Bay LLC, the Lawsuit Settlement Funding Company which operates lawsuitssettlementfunding.com, reported today that Johnson & Johnson has started the process of settling morcellator suits against them.
JNJ: 108.20 (-0.78)
Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain
PR Newswire - Thu Mar 31, 3:10PM CDT
Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that it is discontinuing the Phase 3 development program for fulranumab in osteoarthritis pain. This decision was based on strategic portfolio prioritization and was not based on any emerging safety concerns from the Phase 3 clinical studies with fulranumab. Janssen Pharmaceuticals, Inc., an affiliated company, is terminating its licensing agreement with Amgen Inc. for fulranumab and is returning all program rights back to Amgen.
JNJ: 108.20 (-0.78), AMGN: 149.93 (+0.45)
Johnson & Johnson Correction Could Equal Buying Opportunity
at The Street - Thu Mar 31, 2:16PM CDT
Shares of the pharmaceutical company are headed in the right direction, but the pace of the rally is slowing.
JNJ: 108.20 (-0.78)
Potential Johnson & Johnson Correction Could Equal Buying Opportunity
at The Street - Thu Mar 31, 2:16PM CDT
Shares of the pharmaceutical company are headed in the right direction, but the pace of the rally is slowing.
JNJ: 108.20 (-0.78)
Pfizer Tops List of Best Biopharmaceutical Brands
at The Street - Thu Mar 31, 1:09PM CDT
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.
JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), AZN: 28.16 (-0.16), MRK: 52.91 (-0.31), PFE: 29.64 (-0.43), AMGN: 149.93 (+0.45), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11)
Jim Cramer: Johnson & Johson, IBM, Alphabet Are Cheaper Than You Think
at The Street - Thu Mar 31, 11:35AM CDT
Jim Cramer discusses why stocks like Johnson & Johnson, IBM and Alphabet are cheap as we head into the second quarter.
JNJ: 108.20 (-0.78), GE: 31.79 (-0.04), CLX: 126.06 (-1.91), IBM: 151.45 (+3.04), DAL: 48.68 (-0.65), UNH: 128.90 (-0.78), KMB: 134.51 (-1.20), MCD: 125.68 (-0.15), AAL: 41.01 (-0.37), GOOGL: 762.90 (-5.44), VZ: 54.08 (+0.04), UAL: 59.86 (+0.04)
Medivation Surges on Takeover Chatter; Wall Street Scouts for Big Pharma M&A
at The Street - Thu Mar 31, 7:10AM CDT
Medivation is surging as Wall Street scouts the Big Pharma front for discounted M&A opportunities.
MDVN: 45.98 (+8.59), JNJ: 108.20 (-0.78), VRX: 26.30 (-0.77)
Jim Cramer's 'Mad Money' Recap: Here's How Janet Yellen Set You Free
at The Street - Wed Mar 30, 7:13PM CDT
We no longer have to fear the Fed because the central bank has acknowledged our economy is fragile and the strong U.S. dollar is only making things worse, says Cramer.
KMI: 17.86 (unch), MMM: 166.63 (-0.12), GE: 31.79 (-0.04), ETN: 62.56 (-0.19), EW: 88.21 (-0.68), LLY: 72.01 (+0.23), XRX: 11.16 (+0.33), SCI: 24.68 (+0.33), MTZ: 20.24 (+0.07), PVH: 99.06 (+0.14), NFLX: 102.23 (+0.04), JNJ: 108.20 (-0.78), PAYX: 54.01 (+0.72), TJX: 78.35 (-0.33), DPZ: 131.86 (+0.89), HBI: 28.34 (-0.14), ROST: 57.90 (-0.44)
Cramer Says Stryker an Attractive Target for Johnson & Johnson
at The Street - Wed Mar 30, 2:58PM CDT
As Johnson & Johnson surveys the M&A scene, investors would be wise to keep Stryker on their radars, Real Money's Jim Cramer says.
JNJ: 108.20 (-0.78), SYK: 107.29 (+0.24)
Kellton Tech Enriches SAP Expertise Through Acquisitions
PRWeb - Wed Mar 30, 8:55AM CDT
Kellton Tech, a global, publicly listed IT company based in Hyderabad, India, successively acquired two US-based enterprise solutions providers in the last year to strengthen its capabilities in SAP.
JNJ: 108.20 (-0.78), NWL: 44.29 (-0.08)
4 Value Stocks to Buy Now
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:43AM CDT
U.S. stock markets have been choppy this year, thanks to gyrations in oil price movements. This volatility makes investing in value stocks more appealing.
HCA: 78.05 (-0.05), JNJ: 108.20 (-0.78), GILD: 91.86 (-0.11), TGT: 82.28 (-1.32)
X-Chem Announces License with Janssen for Protein
rotein Inhibitor Program in Inflammatory Disease BusinessWire - Wed Mar 30, 7:15AM CDT
X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX(TM)) drug discovery platform to generate novel therapeutics, today announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been exercised for a protein inhibitor program of inflammatory disease. The licensed program comprises cell-active, potent small molecules that inhibit a difficult-to-drug protein ligand-receptor interaction. Janssen exercised its license option under an agreement to discover new treatments for inflammatory disease established by the companies in December 2014. The licensing event triggers a milestone payment under the collaboration agreement; X-Chem is eligible to receive future payments linked to the achievement of defined milestones, as well as royalties.
JNJ: 108.20 (-0.78)
Global Antibiotics Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Bayer Healthcare, GlaxoSmithKline, Johnson & Johnson - Research and Markets
BusinessWire - Tue Mar 29, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3g2qr4/antibiotics) has announced the addition of the "Antibiotics: Technologies and Global Markets" report to their offering.
JNJ: 108.20 (-0.78), GSK: 40.55 (-0.15)
How 16 Ex-Military CEOs are Trouncing Wall Street
at The Street - Mon Mar 28, 3:44PM CDT
Putting your money into these 16 companies, whose CEOs served in the U.S. military, would have left you (a lot) richer than just following the S&P 500.
FDX: 162.72 (+1.15), NSC: 83.25 (-1.50), CAM: 67.05 (-0.63), AAP: 160.34 (-3.45), PCG: 59.72 (+0.28), SNA: 156.99 (-1.55), RTN: 122.63 (-1.13), AMT: 102.37 (+0.06), SLB: 73.75 (-0.66), CELG: 100.09 (+1.29), SJM: 129.84 (-0.34), JNJ: 108.20 (-0.78), VNO: 94.43 (+0.46), CSC: 34.39 (+0.36), EQIX: 330.71 (+2.60), CSRA: 26.90 (-0.29), VZ: 54.08 (+0.04)
Johnson & Johnson to Webcast Annual Meeting of Shareholders
PR Newswire - Mon Mar 28, 3:44PM CDT
Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10:00 a.m. (EDT) on Thursday, April 28, 2016, from the State Theatre in New Brunswick, N.J.
JNJ: 108.20 (-0.78)
Shock and Awe: West Point Grads Use Military Strategy to Win Big as CEOs
at The Street - Mon Mar 28, 3:23PM CDT
How can West Point help your stock returns? West Point graduates leading Johnson & Johnson, Equinix, and Cameron International posted an average yearly return of 34% while the S&P declined.
JNJ: 108.20 (-0.78), CAM: 67.05 (-0.63), EQIX: 330.71 (+2.60)
Rising Through the Ranks: Interview with Johnson & Johnson CEO Alex Gorsky
at The Street - Mon Mar 28, 3:20PM CDT
Influenced by his father's service in the Korean War, Alex Gorsky said that since he was a boy he dreamed of attending the U.S. Military Academy at West Point.
JNJ: 108.20 (-0.78)
ADM Board of Directors Nominates Debra A. Sandler to Board
BusinessWire - Mon Mar 28, 10:00AM CDT
Archer Daniels Midland Company (NYSE: ADM) today announced that its Board of Directors has nominated Debra A. Sandler to stand for election to the board at its upcoming Annual Stockholders' Meeting on May 5, 2016. Sandler's prior experience includes senior leadership positions at Mars, Inc., Johnson & Johnson, and PepsiCo. Most recently she served as Chief Health and Wellbeing Officer at Mars, after serving there as Chief Consumer Officer and President of Mars Chocolate North America. Sandler currently sits on the board of Gannett Co., Inc.
JNJ: 108.20 (-0.78), ADM: 36.31 (-0.31), GCI: 15.14 (-0.26)
4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 108.20 (-0.78), VRX: 26.30 (-0.77), SYN: 2.36 (+0.03), GERN: 2.92 (+0.05), AMGN: 149.93 (+0.45), EPZM: 12.12 (+0.61), CORT: 4.68 (+0.41)
Legal-Bay Says J&J Moves to Settle Morcellator Suits
PR Newswire - Mon Mar 28, 4:00AM CDT
Legal-Bay LLC, the Lawsuit Settlement Funding Company which operates lawsuitssettlementfunding.com, reported today that Johnson & Johnson has started the process of settling morcellator suits against them.
JNJ: 108.20 (-0.78)
